HK1216755A1 - 輔助性 細胞的活化方法 - Google Patents

輔助性 細胞的活化方法

Info

Publication number
HK1216755A1
HK1216755A1 HK16104510.5A HK16104510A HK1216755A1 HK 1216755 A1 HK1216755 A1 HK 1216755A1 HK 16104510 A HK16104510 A HK 16104510A HK 1216755 A1 HK1216755 A1 HK 1216755A1
Authority
HK
Hong Kong
Prior art keywords
helper cell
activating helper
activating
cell
helper
Prior art date
Application number
HK16104510.5A
Other languages
English (en)
Inventor
Hiroshi Kubo
Shinji Sogo
Haruo Sugiyama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1216755A1 publication Critical patent/HK1216755A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464452Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK16104510.5A 2012-12-17 2016-04-20 輔助性 細胞的活化方法 HK1216755A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012274494 2012-12-17
PCT/JP2013/083580 WO2014098012A1 (ja) 2012-12-17 2013-12-16 ヘルパーt細胞の活性化方法

Publications (1)

Publication Number Publication Date
HK1216755A1 true HK1216755A1 (zh) 2016-12-02

Family

ID=50978342

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104510.5A HK1216755A1 (zh) 2012-12-17 2016-04-20 輔助性 細胞的活化方法

Country Status (21)

Country Link
US (1) US9833493B2 (zh)
EP (1) EP2933261B1 (zh)
JP (1) JP6530192B2 (zh)
KR (1) KR102158225B1 (zh)
CN (2) CN104995203B (zh)
AR (1) AR094026A1 (zh)
AU (1) AU2013365067B2 (zh)
BR (1) BR112015013697A2 (zh)
CA (1) CA2892660C (zh)
EA (1) EA201591168A1 (zh)
ES (1) ES2805337T3 (zh)
HK (1) HK1216755A1 (zh)
IL (1) IL239056A0 (zh)
MX (1) MX2015007745A (zh)
MY (1) MY175935A (zh)
NZ (1) NZ708990A (zh)
PH (1) PH12015501361A1 (zh)
SG (2) SG11201504530VA (zh)
TW (1) TWI646970B (zh)
UA (1) UA118962C2 (zh)
WO (1) WO2014098012A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
KR102171794B1 (ko) 2010-10-05 2020-10-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 t 세포의 활성화 방법
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
SG11201504530VA (en) 2012-12-17 2015-07-30 Otsuka Pharma Co Ltd Method for activating helper t cell
JP6486278B2 (ja) 2013-01-15 2019-03-20 メモリアル スローン ケタリング キャンサー センター 免疫原性wt−1ペプチドおよびその使用法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR20230141904A (ko) * 2014-12-11 2023-10-10 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
CA3228494A1 (en) 2021-08-12 2023-02-16 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treating or preventing cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
KR100767554B1 (ko) 1998-07-31 2007-10-17 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
JP4243792B2 (ja) 1998-09-30 2009-03-25 コリクサ コーポレイション Wt1特異的免疫療法のための組成物および方法
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
JP2003524021A (ja) 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP2014300B1 (en) 2001-06-29 2011-01-12 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的t細胞の誘導方法
CA2489227C (en) 2002-06-12 2012-03-13 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptides
JP4611022B2 (ja) 2002-09-12 2011-01-12 株式会社癌免疫研究所 癌抗原ペプチド製剤
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
EP2154145B1 (en) 2003-01-15 2013-04-24 International Institute of Cancer Immunology, Inc. Dimerized peptide
JP4566912B2 (ja) 2003-06-27 2010-10-20 株式会社癌免疫研究所 Wt1ワクチン適応患者の選択方法
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Hlaクラスii拘束性wt1抗原ペプチド
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
US8759483B2 (en) 2006-02-22 2014-06-24 International Institute Of Cancer Immunology, Inc. HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP3117836A1 (en) * 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CA2886622A1 (en) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
MX2009009589A (es) 2007-03-05 2009-09-21 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
KR102171794B1 (ko) * 2010-10-05 2020-10-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 t 세포의 활성화 방법
SG11201504530VA (en) 2012-12-17 2015-07-30 Otsuka Pharma Co Ltd Method for activating helper t cell

Also Published As

Publication number Publication date
SG11201504530VA (en) 2015-07-30
JP6530192B2 (ja) 2019-06-12
KR102158225B1 (ko) 2020-09-21
CA2892660A1 (en) 2014-06-26
CA2892660C (en) 2022-02-15
JPWO2014098012A1 (ja) 2017-01-12
EP2933261A4 (en) 2016-07-06
ES2805337T3 (es) 2021-02-11
SG10201705028WA (en) 2017-07-28
EP2933261A1 (en) 2015-10-21
IL239056A0 (en) 2015-07-30
TW201429487A (zh) 2014-08-01
NZ708990A (en) 2020-03-27
AU2013365067B2 (en) 2017-10-05
UA118962C2 (uk) 2019-04-10
CN110195040A (zh) 2019-09-03
KR20150096697A (ko) 2015-08-25
WO2014098012A1 (ja) 2014-06-26
US9833493B2 (en) 2017-12-05
CN104995203A (zh) 2015-10-21
AR094026A1 (es) 2015-07-08
TWI646970B (zh) 2019-01-11
EA201591168A1 (ru) 2016-05-31
AU2013365067A1 (en) 2015-07-09
US20150328278A1 (en) 2015-11-19
MY175935A (en) 2020-07-15
EP2933261B1 (en) 2020-06-10
PH12015501361B1 (en) 2015-09-02
BR112015013697A2 (pt) 2017-11-14
PH12015501361A1 (en) 2015-09-02
MX2015007745A (es) 2015-12-15
CN104995203B (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
IL245440A0 (en) A method for activating a t-helper cell
HK1216755A1 (zh) 輔助性 細胞的活化方法
ZA201501833B (en) Method for obtaining 1-kestone
EP2839016A4 (en) CELL TRANSFECTION METHOD
PT2828235T (pt) Processo para a produção de isocianatos
GB201212937D0 (en) Method
GB201212932D0 (en) Method
GB201220940D0 (en) Method P
GB201213636D0 (en) Method
GB201212934D0 (en) Method
GB201210858D0 (en) Method
GB201218570D0 (en) Method
EP2851974A4 (en) METHOD FOR PRODUCING A CELL
EP2880048A4 (en) METHOD
EP2928294A4 (en) CELL METHOD
GB201202198D0 (en) Method
GB201211393D0 (en) Method
GB201217688D0 (en) Method
GB201214029D0 (en) method
GB201210147D0 (en) Method
GB201220282D0 (en) Electrochemical method
GB201213858D0 (en) Method
GB201203337D0 (en) Method
GB201201332D0 (en) Method
EP2639418A4 (en) EXHAUST HEATING METHOD